Literature DB >> 17114476

Direct CD28 costimulation is required for CD8+ T cell-mediated resistance to an acute viral disease in a natural host.

Min Fang1, Luis J Sigal.   

Abstract

Previous studies have suggested that, differing from model Ags, viruses that replicate extensively in the host still induce normal CD8+ T cell responses in the absence of CD28 costimulation. Because these studies were performed with viruses that do not normally cause acute disease, an important remaining question is whether CD28 costimulation is required for CD8+ T cell-mediated resistance to widely replicating but pathogenic viruses. To address this question, we studied the role of CD28 costimulation in CD8+ T cell-mediated resistance to mousepox, a disease of the mouse caused by the natural mouse pathogen, the ectromelia virus (ECTV). C57BL/6 (B6) mice are naturally resistant to mousepox, partly due to a fast and strong CD8+ T cell response. We found that B6 mice deficient in CD28 (CD28 knockout (KO)) are highly susceptible to lethal mousepox during the early stages of ECTV infection but can be protected by immunization with the antigenically related vaccinia virus (VACV) or by adoptive transfer of CD28 KO anti-VACV memory CD8+ cells. Of interest, a thorough comparison of the CD8+ T cell responses to ECTV and VACV suggests that the main reason for the susceptibility of CD28 KO mice to mousepox is a reduced response at the early stages of infection. Thus, while in the absence of CD28 costimulation the end point strength of the T cell responses to nonpathogenic viruses may appear normal, CD28 costimulation increases the speed of the T cell response and is essential for resistance to a life-threatening acute viral disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17114476     DOI: 10.4049/jimmunol.177.11.8027

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

1.  Perforin-dependent CD4+ T-cell cytotoxicity contributes to control a murine poxvirus infection.

Authors:  Min Fang; Nicholas A Siciliano; Adam R Hersperger; Felicia Roscoe; Angela Hu; Xueying Ma; Ahamed R Shamsedeen; Laurence C Eisenlohr; Luis J Sigal
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-04       Impact factor: 11.205

2.  The TNFR family members OX40 and CD27 link viral virulence to protective T cell vaccines in mice.

Authors:  Shahram Salek-Ardakani; Rachel Flynn; Ramon Arens; Hideo Yagita; Geoffrey L Smith; Jannie Borst; Stephen P Schoenberger; Michael Croft
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

3.  Comparable polyfunctionality of ectromelia virus- and vaccinia virus-specific murine T cells despite markedly different in vivo replication and pathogenicity.

Authors:  Adam R Hersperger; Nicholas A Siciliano; Laurence C Eisenlohr
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

4.  Memory CD8+ T cells specific for a single immunodominant or subdominant determinant induced by peptide-dendritic cell immunization protect from an acute lethal viral disease.

Authors:  Sanda Remakus; Daniel Rubio; Xueying Ma; Alessandro Sette; Luis J Sigal
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

5.  Differential requirements for CD80/86-CD28 costimulation in primary and memory CD4 T cell responses to vaccinia virus.

Authors:  Shinichiro Fuse; Ching-Yi Tsai; Leah M Rommereim; Weijun Zhang; Edward J Usherwood
Journal:  Cell Immunol       Date:  2010-10-30       Impact factor: 4.868

6.  Induction of death receptor CD95 and co-stimulatory molecules CD80 and CD86 by meningococcal capsular polysaccharide-loaded vaccine nanoparticles.

Authors:  Ruhi V Ubale; Rikhav P Gala; Susu M Zughaier; Martin J D'Souza
Journal:  AAPS J       Date:  2014-07-01       Impact factor: 4.009

7.  Characterization of ectromelia virus deficient in EVM036, the homolog of vaccinia virus F13L, and its application for rapid generation of recombinant viruses.

Authors:  Felicia Roscoe; Ren-Huan Xu; Luis J Sigal
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

8.  Preferential use of B7.2 and not B7.1 in priming of vaccinia virus-specific CD8 T cells.

Authors:  Shahram Salek-Ardakani; Ramon Arens; Rachel Flynn; Alessandro Sette; Stephen P Schoenberger; Michael Croft
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

9.  Vaccinia virus A35R inhibits MHC class II antigen presentation.

Authors:  Kristina E Rehm; Ramsey F Connor; Gwendolyn J B Jones; Kenneth Yimbu; Rachel L Roper
Journal:  Virology       Date:  2009-12-02       Impact factor: 3.616

10.  Direct presentation is sufficient for an efficient anti-viral CD8+ T cell response.

Authors:  Ren-Huan Xu; Sanda Remakus; Xueying Ma; Felicia Roscoe; Luis J Sigal
Journal:  PLoS Pathog       Date:  2010-02-12       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.